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We  determined  the  prevalence  of  plasmid-mediated 
quinolone  resistance  mechanisms  among  non-Typhi  Sal-
monella spp. isolated from humans, food animals, and retail 
meat in the United States in 2007. Six isolates collected from 
humans harbored aac(6′)Ib-cr or a qnr gene. Most prevalent 
was qnrS1. No animal or retail meat isolates harbored a 
plasmid-mediated mechanism.
S
evere Salmonella enterica infections are commonly 
treated  with  fluoroquinolones  (e.g.,  ciprofloxacin) 
(1). In the United States, the antimicrobial drug suscep-
tibility of Salmonella spp. isolated from humans, food 
animals, and retail meats is systematically monitored by 
the National Antimicrobial Resistance Monitoring Sys-
tem (NARMS). This program is a collaborative effort of 
the Centers for Disease Control and Prevention (CDC), 
the Food and Drug Administration Center for Veterinary 
Medicine (FDA-CVM) and the US Department of Agri-
culture (USDA). Antimicrobial susceptibility to fluoro-
quinolones among Salmonella spp. has been monitored 
since the program’s inception in 1996.
Although fluoroquinolone resistance in Enterobacte-
riaceae is predominantly due to topoisomerase mutations, 
3 plasmid-mediated mechanisms have been described that 
confer decreased susceptibility to ciprofloxacin: quinolone 
resistance proteins (Qnr), Aac(6′)-Ib-cr, and QepA efflux 
(2). The Qnr proteins protect the DNA-gyrase from quino-
lones, Aac(6′)-Ib-cr modifies quinolones with a piperazinyl 
group, and QepA is involved in active efflux (2). Because 
patients have experienced treatment failure when infected 
with Salmonella isolates that displayed decreased suscep-
tibility to fluoroquinolones, plasmid-mediated mechanisms 
are clinically relevant (3).
A survey of 12,253 NARMS non-Typhi Salmonella 
(NTS) isolates collected from humans from 1996 through 
2003 identified 10 (0.08%) qnr-positive isolates (4). A sec-
ond survey of NARMS NTS collected from humans during 
2004–2006 showed an increase in the proportion of isolates 
harboring plasmid-mediated quinolone resistance mecha-
nisms. Among 6,057 isolates, 17 qnr-positive isolates and 
1 aac(6′)-Ib-cr-positive isolate were detected, representing 
0.3% of the NTS collected during that time (5).
The increase in plasmid-mediated quinolone resistance 
among  NTS  isolated  from  humans  in  the  United  States 
prompted  further  studies  to  determine  continued  pres-
ence among NTS of human origin and possible reservoirs 
of these mechanisms. In this study, we investigated plas-
mid-mediated  quinolone  resistance  mechanisms  among 
NARMS NTS isolated from humans, food animals, and 
retail meat in the United States in 2007.
The Study
In 2007, 54 NARMS-participating public health labo-
ratories from all 50 states forwarded every 20th human 
isolate of NTS to CDC. Similarly, NTS isolated from re-
tail meat (chicken breasts, ground turkey, ground beef, 
and pork chops) were submitted by 10 states that partici-
pated in CDC’s Foodborne Diseases Active Surveillance 
Network (FoodNet) for analysis at FDA-CVM. NTS from 
food animals were obtained from carcass rinsates (chick-
en), carcass swab specimens (turkey, cattle, and swine), 
and ground products (chicken, turkey, and beef). Animal 
samples  were  collected  by  the  Food  Safety  Inspection 
Service of the USDA from federally inspected slaughter 
and processing plants throughout the United States and 
sent to USDA facilities in Athens, Georgia, for further 
analysis.
At each agency, MICs were determined by broth mi-
crodilution (Sensititer; Trek Diagnostics, Westlake, OH, 
USA). Human, animal, and retail meat isolates of NTS 
that  displayed  decreased  susceptibility  to  ciprofloxacin 
(MIC >0.25 mg/L) were included in our study. For each 
isolate, genomic DNA was prepared by lysing the bacteria 
at 95°C and collecting the supernatant after centrifuga-
tion. PCRs with previously described primers were used 
to screen isolates for qepA, aac(6′)-Ib-cr, and qnr genes 
(qnrA, B, C, D, S) (6–10). Positive controls were included 
for qepA (Escherichia coli TOP10 pAT851), qnrA (S. en-
terica serotype Montevideo AM28704), qnrB (S. enterica 
serotype  Berta  AM04589),  qnrS ( S.  enterica  serotype 
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36564). For isolates with positive results in the screening, 
amplicons were confirmed by direct sequencing by using 
a 3730 DNA Analyzer (Applied Biosystems, Foster City, 
CA, USA).
Among 2,165 isolates of NTS collected from humans 
in 2007, 51 (2.4%) displayed decreased susceptibility to 
ciprofloxacin. Among 320 NTS obtained from retail meat, 
5 (1.6%) showed decreased susceptibility to ciprofloxa-
cin, and among the 1,915 isolates obtained from animal 
sources, 5 (0.3%) showed such susceptibility. Six (11.8%) 
of  the  51  human  isolates  carried  a  plasmid-mediated 
mechanism that affected quinolones; 5 isolates harbored 
a qnr gene, and 1 isolate contained the aac(6′)-Ib-cr gene 
(Table). None of the isolates harbored the qepA gene. Se-
quencing of the 5 qnr-positive isolates showed 3 qnrS and 
2 qnrB variants among 4 serotypes (Beaudesert, Corvallis, 
Enteritidis, and Typhimurium) (Table). The aac(6’)-Ib-cr 
gene was found in an isolate of serotype Thompson, and 
sequencing confirmed the 2 point mutations (Trp102Arg 
and  Asp179Tyr)  characteristic  of  the  ciprofloxacin-
modifying variant. The MIC of ciprofloxacin among the 
qnr-positive isolates ranged from 0.25 mg/L to 0.5 mg/L, 
whereas  the  aac(6′)-Ib-cr–positive  isolate  displayed  an 
MIC of 0.5 mg/L. All isolates from humans were suscep-
tible to nalidixic acid (MIC range 8–16 mg/L). None of the 
isolates obtained from retail meat or those isolated from 
animal sources harbored plasmid-mediated mechanisms 
affecting quinolones. However, all retail meat and ani-
mal isolates with decreased susceptibility to ciprofloxacin 
were resistant to nalidixic acid (MIC >32 mg/L), which 
suggests the presence of topoisomerase mutations.
The 6 patients (3 male and 3 female) who were in-
fected  with  a  Qnr-producing  or  Aac(6′)-Ib-cr–producing 
Salmonella isolate had a median age of 18 (range 3–84 
years). Three patients were available for interview. They 
reported gastrointestinal symptoms and had sought medical 
care for their condition. Two of the patients had received 
antimicrobial drug treatment (ciprofloxacin and cefdinir, 
respectively); none of the patients developed an invasive 
infection. Two patients reported a history of international 
travel to Mexico and Thailand, respectively.
Conclusions
Six (0.3%) NARMS NTS collected from humans in 
2007  harbored  a  plasmid-mediated  quinolone  resistance 
mechanism,  the  same  prevalence  as  in  2004–2006  (5). 
None of the isolates collected from animal and retail meat 
by the USDA and FDA in 2007 harbored these mechanisms. 
Among the human isolates, qnr genes predominated and 
qnrS1 was most prevalent. This gene has previously been 
described among NARMS human NTS and was first de-
tected in an isolate of serotype Bovismorbificans collected 
in 2000 (4). The gene was later reported in 11 isolates (sero-
types Corvallis, Enteritidis, Montevideo, Saintpaul, and Ty-
phimurium) collected by NARMS during 2004–2006 (5).
That qnr genes could only be detected among Salmo-
nella isolates obtained from humans warrants further ex-
ploration. One factor that could influence the number of 
Qnr-producing Salmonella isolates among humans in the 
United States is the extent of travel-associated infections. 
Two patients in this study had a history of international 
travel before illness onset. Another factor that could lead 
to the development of Qnr-producing Salmonella isolates 
is the in vivo transfer of resistance from other qnr-bearing 
Enterobacteriaceae.
Our study does not suggest that food animals and meat 
in the United States are major sources of Salmonella iso-
lates  that  harbor  plasmid-mediated  quinolone  resistance 
mechanisms. However, animals and food have been de-
scribed  as  reservoirs  for  these  mechanisms  elsewhere. 
A  high  prevalence  of  Enterobacteriaceae  with  qnr  and 
aac(6’)-Ib-cr have been reported among companion and 
food animals in the People’s Republic of China and qnr-
positive Salmonella isolates have been found in poultry in 
Europe (11,12). Thus, other food and meat sources, not in-
vestigated in the current study, may serve as reservoirs for 
these mechanisms.
Fluoroquinolone resistance among isolates of NTS has 
important public health implications because ciprofloxacin 
is commonly used to treat invasive infections of Salmonel-
la spp. in adults. Although plasmid-mediated quinolone re-
sistance mechanisms do not, by themselves, confer clinical 
resistance to ciprofloxacin, they may promote the selection 
of mutations that do (13). In addition, studies have shown 
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Table. Characteristics of non-Typhi Salmonella enterica isolates harboring qnr or the aac(6ƍ)-Ib-cr gene, collected through NARMS, 
2007*
Isolate no.  S. enterica serovar  Submitting site  Resistance phenotype  Ciprofloxacin MIC, mg/L  aac6ƍIb/qnr variant 
AM31035  Thompson  NY  AMP, SUL 0.5 aac(6ƍ)-Ib-cr 
AM30827  Typhimurium  CA STR, SUL, TET  0.5 qnrS1
AM31228  Corvallis  VA ND  0.5 qnrS1
AM33914  Typhimurium  NC  ND  0.5 qnrS1
AM31434  Enteritidis LX SUL, SXT, TET  0.25 qnrB2
AM33097  Beaudesert  CA ND  0.25 qnrB19
*NARMS, National Antimicrobial Resistance Monitoring System; NY, New York; AMP, ampicillin; SUL, sulfamethoxazole or sulfisoxazole; CA, California; 
STR, streptomycin; TET, tetracycline; VA, Virginia; ND, none detected; NC, North Carolina; LX, Los Angeles; SXT, trimethoprim/sulfamethoxazole.  Quinolone-Resistant Salmonella enterica
that patients infected with isolates that display low-level 
fluoroquinolone  resistance  may  respond  poorly  to  treat-
ment, prompting a reconsideration of MIC breakpoints in 
clinical medicine (3,14). To avoid further dissemination of 
plasmid-mediated quinolone resistance among Salmonella 
and other Enterobacteriaceae isolates in the United States, 
prudent use of antimicrobial agents in both human and vet-
erinary medicine will be crucial. Continued surveillance for 
resistant bacteria among human, animal, and food sources 
remains critical.
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